The Histone Deacetylase 8 Market is segmented by application, with cancer treatment currently holding the largest share, driven by the high prevalence of HDAC8 overexpression in various malignancies. According to the MRFR report, the therapeutic applications segment is anticipated to expand rapidly as more preclinical and clinical studies demonstrate the potential benefits of HDAC8 inhibitors, particularly in treating hematological malignancies and solid tumors. The ability to selectively target HDAC8 is expected to improve the safety profile of epigenetic therapies, making them attractive for combination regimens.

While cancer treatment leads, neurological disorders represent a rapidly growing segment. HDAC8 has been implicated in the pathogenesis of Huntington's disease (HD), where its inhibition has been shown to promote the clearance of mutant huntingtin protein. A phase 2 trial of the HDAC inhibitor selisistat found it safe and tolerable in HD patients, and it accomplished something no other experimental treatment has been shown to do—it changed the level of mutant huntingtin in the bloodstream. Although the trial revealed an unexpected increase in the protein level, the results have spurred further investigation into the role of HDAC8 in neurodegeneration. Research has also shown that HDAC8 plays a role in cognitive dysfunction associated with anesthesia, and HDAC8 inhibitors have demonstrated neuroprotective effects in models of Parkinson's disease. Furthermore, a 2025 study published in Nature Communications revealed that selectively inhibiting HDAC8 in Schwann cells could significantly enhance peripheral nerve regeneration after injury, opening up new possibilities for treating traumatic nerve damage.

Rare diseases are also a significant and growing application segment. HDAC8 mutations are responsible for a subset of Cornelia de Lange syndrome (CdLS), a rare developmental disorder. While no HDAC8-targeted therapy is yet approved for CdLS, the FDA's Orphan Drug Designation program is incentivizing development. NBM-BMX, a selective HDAC8 inhibitor developed by NovelWise Pharmaceutical Corporation, has received both Fast Track and Orphan Drug Designations for the treatment of metastatic uveal melanoma, a rare and aggressive cancer with limited treatment options. The first patient was dosed in the Phase Ib/II trial in December 2025, marking a significant clinical milestone.

By end use, the market is dominated by pharmaceutical and biotechnology companies, which are driving the majority of R&D efforts and clinical trials. Research institutions and academic medical centers are also key end-users, contributing to the foundational science and early-stage translational research that underpins the market. As more HDAC8 inhibitors enter clinical development and as regulatory approvals are secured, the market is expected to see a shift toward commercial production and distribution, with hospitals and specialty pharmacies playing an increasingly important role. The expansion into new applications, such as cardiovascular and metabolic diseases, will further diversify the end-user landscape.